Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Dec 5, 2023 01:20AM
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Dec 5, 2023 01:20AM
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Dec 5, 2023 01:20AM
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Dec 5, 2023 01:20AM
Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth Dec 5, 2023 01:20AM
View Older Stories

Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Dec 5, 2023 01:20AM Relief Therapeutics Shifts Commercial Operations to Partnership Model, Focusing on Efficient Patient Access and R&D Growth
Nov 22, 2023 03:00AM Relief Therapeutics Announces CEO Transition
Oct 10, 2023 01:20AM Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Oct 10, 2023 01:20AM Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Oct 10, 2023 01:20AM Relief Therapeutics Announces that more than 400,000 of its ADRs are Currently Outstanding and that, as a Result, the Company has Achieved an Important NASDAQ Initial Listing Milestone
Sep 15, 2023 02:15AM Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Sep 15, 2023 02:15AM Relief Therapeutics Reports Half-Year 2023 Financial Results and Provides Corporate Update
Sep 1, 2023 03:15AM Relief Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Aug 30, 2023 05:40PM Relief Therapeutics Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics
Jul 19, 2023 02:00AM Relief Therapeutics Announces Extension of Distribution Agreement for PKU GOLIKE(R) in the U.S. with Pentec Health
Jun 20, 2023 05:20AM RELIEF THERAPEUTICS Holding SA Announces Results of Annual General Meeting of Shareholders
May 3, 2023 01:30AM Relief Therapeutics Announces Implementation Timeline for Reverse Split of Ordinary Shares
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
May 1, 2023 01:10AM Relief Therapeutics Announces Collaboration Partner Reports OLPRUVA(TM) Commercial Launch Progressing Ahead of Schedule
Apr 28, 2023 01:20PM Relief Therapeutics Announces Results of Extraordinary General Meeting of Shareholders
Apr 17, 2023 05:31AM Relief Therapeutics (RLFTF) Reports Positive 12-Month Stability Data for Inhaled and Intravenous RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
Apr 17, 2023 01:20AM Relief Therapeutics Announces Positive 12-Month Stability Data for Inhaled and Intravenous Preparations of RLF-100
View Older Stories